The Effects of Iontophoresed Vasoactive Drugs on Cutaneus Blood Flow (Jonto01)
Cardiovascular Diseases, Vascular Diseases
About this trial
This is an interventional basic science trial for Cardiovascular Diseases focused on measuring iontophoresis, pharmacology, tissue viability imaging, multi-exposure laser speckle contrast imaging
Eligibility Criteria
Inclusion Criteria:
- Healthy
- No ongoing medication
- No skin disease or other skin afflictions
- Informed, voluntary participation
Exclusion Criteria:
- Ongoing medication (contraceptives excluded)
- Hypertonia, skin disease or skin afflictions, cardiovascular disease, pregnancy
- Damaged skin, bruises, scar tissue or tattoos on the skin of the forearms
- Smoking (6 months prior to study onset, or more than 100 cigarettes in life)
- Snus (6 months prior to study onset)
- Use of nicotine products (gum, patch, et cetera) 6 months prior to study onset
- Blood pressure above 140/90
- Coffee, tea, alcohol or strenuous physical activity on the day of the study
- Not fasting for 2 hours prior onset of the study
Sites / Locations
- University Hospital LinköpingRecruiting
Arms of the Study
Arm 1
Experimental
Vascular effects of iontophoresed vasoactive substances
Iontophoretically administered vasoactive substances in five concentrations (1%,0.1%,0.01%,0.001%, 0.0001%) dissolved in sterile water. Each concentration of the drug is separately administered using a electrical charge of 12 millicoulomb (mC) (600 seconds x 0.02 milliampere) for 3 repeated pulses (total electrical charge 36 mC). Each iontophoresis pulse is separated by a 30 minute wash-out period. Vasoactive substances: Miochol-E (Acetylcholine),10 mg/ml, Bausch & Lomb Methacholine chloride, 100 mg/ml, APL Norepinephrine, 1 mg/ml, Pfizer Phenylephrine, 10 mg/ml, Unimedic Atropine, 10 mg/ml, Bausch & Lomb Neostigmine, 2.5 mg/ml, Unimedic Pharma Sterile water, 100 ml, Braun